Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,626 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).
Tanzawa S, Makiguchi T, Tasaka S, Inaba M, Ochiai R, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Miyamoto Y, Yokoyama T, Matsumoto C, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Misumi T, Shiraishi K, Matsutani N, Seki N. Tanzawa S, et al. Among authors: tsuda t. Ther Adv Med Oncol. 2022 Jul 29;14:17588359221116603. doi: 10.1177/17588359221116603. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35923924 Free PMC article.
A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations.
Imai H, Kaira K, Suzuki K, Anzai M, Tsuda T, Ishizuka T, Kuwako T, Naruse I, Nemoto K, Uchino J, Morozumi N, Ishihara S, Minato K, Hisada T. Imai H, et al. Among authors: tsuda t. Lung Cancer. 2018 Dec;126:41-47. doi: 10.1016/j.lungcan.2018.10.014. Epub 2018 Oct 13. Lung Cancer. 2018. PMID: 30527191 Clinical Trial.
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study).
Tanzawa S, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Misumi T, Shiraishi K, Matsutani N, Tanaka H, Inaba M, Haruyama T, Nakamura J, Kishikawa T, Nakashima M, Iwasa K, Fujiwara K, Kohyama T, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Ishida H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Fujimoto N, Yokoyama T, Gemba K, Tsuda T, Nakagawa H, Ono H, Shimizu T, Nakamura M, Kusumoto S, Hayashi R, Shirasaki H, Ochi N, Aoe K, Kanaji N, Kashiwabara K, Inoue H, Seki N. Tanzawa S, et al. Among authors: tsuda t. Ther Adv Med Oncol. 2021 Feb 27;13:1758835921998588. doi: 10.1177/1758835921998588. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33717228 Free PMC article.
Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer.
Shiono A, Imai H, Wasamoto S, Tsuda T, Nagai Y, Minemura H, Yamada Y, Kishikawa T, Umeda Y, Takechi H, Yamaguchi O, Mouri A, Kaira K, Taniguchi H, Minato K, Kagamu H. Shiono A, et al. Among authors: tsuda t. Cancer Med. 2023 Jan;12(1):73-83. doi: 10.1002/cam4.4938. Epub 2022 Jun 14. Cancer Med. 2023. PMID: 35699088 Free PMC article.
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.
Imai H, Nagai Y, Minemura H, Tsuda T, Yamada Y, Wasamoto S, Kishikawa T, Shiono A, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Minato K, Kagamu H. Imai H, et al. Among authors: tsuda t. Invest New Drugs. 2022 Oct;40(5):1066-1079. doi: 10.1007/s10637-022-01269-9. Epub 2022 Jun 24. Invest New Drugs. 2022. PMID: 35749041 Free PMC article.
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Masubuchi K, Imai H, Wasamoto S, Tsuda T, Minemura H, Nagai Y, Yamada Y, Kishikawa T, Umeda Y, Shiono A, Takechi H, Shiihara J, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Kagamu H, Minato K. Masubuchi K, et al. Among authors: tsuda t. Thorac Cancer. 2022 Oct;13(19):2776-2785. doi: 10.1111/1759-7714.14621. Epub 2022 Sep 5. Thorac Cancer. 2022. PMID: 36062426 Free PMC article.
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis.
Tanaka H, Tanzawa S, Misumi T, Makiguchi T, Inaba M, Honda T, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Fujimoto N, Fukuda Y, Yasugi M, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Shiraishi K, Matsutani N, Seki N. Tanaka H, et al. Among authors: tsuda t. Ther Adv Med Oncol. 2022 Dec 18;14:17588359221142786. doi: 10.1177/17588359221142786. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36570411 Free PMC article.
Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.
Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Minato K, Kagamu H. Wasamoto S, et al. Among authors: tsuda t. Front Oncol. 2023 Jan 20;12:1080729. doi: 10.3389/fonc.2022.1080729. eCollection 2022. Front Oncol. 2023. PMID: 36741711 Free PMC article.
Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL).
Miura S, Nishio M, Akamatsu H, Goto Y, Hayashi H, Gemma A, Yoshino I, Misumi T, Hata A, Hataji O, Fujita K, Seike M, Yanagitani N, Nishino K, Hara S, Saito R, Mori M, Tsuda T, Iwasawa S, Nakagawa S, Mitsudomi T. Miura S, et al. Among authors: tsuda t. JTO Clin Res Rep. 2023 Feb 24;4(3):100484. doi: 10.1016/j.jtocrr.2023.100484. eCollection 2023 Mar. JTO Clin Res Rep. 2023. PMID: 37034464 Free PMC article.
1,626 results